Literature DB >> 21799478

Intermittent hypoxia exacerbates metabolic effects of diet-induced obesity.

Luciano F Drager1, Jianguo Li, Christian Reinke, Shannon Bevans-Fonti, Jonathan C Jun, Vsevolod Y Polotsky.   

Abstract

Obesity causes insulin resistance (IR) and nonalcoholic fatty liver disease (NAFLD), but the relative contribution of sleep apnea is debatable. The main aim of this study is to evaluate the effects of chronic intermittent hypoxia (CIH), a hallmark of sleep apnea, on IR and NAFLD in lean mice and mice with diet-induced obesity (DIO). Mice (C57BL/6J), 6-8 weeks of age were fed a high fat (n = 18) or regular (n = 16) diet for 12 weeks and then exposed to CIH or control conditions (room air) for 4 weeks. At the end of the exposure, fasting (5 h) blood glucose, insulin, homeostasis model assessment (HOMA) index, liver enzymes, and intraperitoneal glucose tolerance test (1 g/kg) were measured. In DIO mice, body weight remained stable during CIH and did not differ from control conditions. Lean mice under CIH were significantly lighter than control mice by day 28 (P = 0.002). Compared to lean mice, DIO mice had higher fasting levels of blood glucose, plasma insulin, the HOMA index, and had glucose intolerance and hepatic steatosis at baseline. In lean mice, CIH slightly increased HOMA index (from 1.79 ± 0.13 in control to 2.41 ± 0.26 in CIH; P = 0.05), whereas glucose tolerance was not affected. In contrast, in DIO mice, CIH doubled HOMA index (from 10.1 ± 2.1 in control to 22.5 ± 3.6 in CIH; P < 0.01), and induced severe glucose intolerance. In DIO mice, CIH induced NAFLD, inflammation, and oxidative stress, which was not observed in lean mice. In conclusion, CIH exacerbates IR and induces steatohepatitis in DIO mice, suggesting that CIH may account for metabolic dysfunction in obesity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21799478      PMCID: PMC4461029          DOI: 10.1038/oby.2011.240

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  48 in total

1.  Metformin reverses fatty liver disease in obese, leptin-deficient mice.

Authors:  H Z Lin; S Q Yang; C Chuckaree; F Kuhajda; G Ronnet; A M Diehl
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

2.  Intermittent hypoxia induces hyperlipidemia in lean mice.

Authors:  Jianguo Li; Laura N Thorne; Naresh M Punjabi; Cheuk-Kwan Sun; Alan R Schwartz; Philip L Smith; Rafael L Marino; Annabelle Rodriguez; Walter C Hubbard; Christopher P O'Donnell; Vsevolod Y Polotsky
Journal:  Circ Res       Date:  2005-08-25       Impact factor: 17.367

3.  A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats.

Authors:  Michal Carmiel-Haggai; Arthur I Cederbaum; Natalia Nieto
Journal:  FASEB J       Date:  2004-11-02       Impact factor: 5.191

4.  Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance.

Authors:  Roger Gutiérrez-Juárez; Alessandro Pocai; Claudia Mulas; Hiraku Ono; Sanjay Bhanot; Brett P Monia; Luciano Rossetti
Journal:  J Clin Invest       Date:  2006-06       Impact factor: 14.808

5.  The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes.

Authors:  Igor Alexander Harsch; Simin Pour Schahin; Kerstin Brückner; Martin Radespiel-Tröger; Florian S Fuchs; Eckhart Georg Hahn; Peter Christopher Konturek; Tobias Lohmann; Joachim Hans Ficker
Journal:  Respiration       Date:  2004 May-Jun       Impact factor: 3.580

6.  Intermittent hypoxia increases insulin resistance in genetically obese mice.

Authors:  Vsevolod Y Polotsky; Jianguo Li; Naresh M Punjabi; Arnon E Rubin; Philip L Smith; Alan R Schwartz; Christopher P O'Donnell
Journal:  J Physiol       Date:  2003-07-23       Impact factor: 5.182

7.  Chronic intermittent hypoxia predisposes to liver injury.

Authors:  Vladimir Savransky; Ashika Nanayakkara; Angelica Vivero; Jianguo Li; Shannon Bevans; Philip L Smith; Michael S Torbenson; Vsevolod Y Polotsky
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

8.  Obstructive sleep apnoea (OSA) patterns in bariatric surgical practice and response of OSA to weight loss after laparoscopic adjustable gastric banding (LAGB).

Authors:  A Rao; Beng Hea Tey; Ganesh Ramalingam; Aaron G H Poh
Journal:  Ann Acad Med Singapore       Date:  2009-07       Impact factor: 2.473

9.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans.

Authors:  R V Considine; M K Sinha; M L Heiman; A Kriauciunas; T W Stephens; M R Nyce; J P Ohannesian; C C Marco; L J McKee; T L Bauer
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245

10.  Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver.

Authors:  Vladimir Savransky; Shannon Bevans; Ashika Nanayakkara; Jianguo Li; Philip L Smith; Michael S Torbenson; Vsevolod Y Polotsky
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-08-09       Impact factor: 4.052

View more
  89 in total

Review 1.  Sleep Apnea Research in Animals. Past, Present, and Future.

Authors:  Swati Chopra; Vsevolod Y Polotsky; Jonathan C Jun
Journal:  Am J Respir Cell Mol Biol       Date:  2016-03       Impact factor: 6.914

Review 2.  Translational approaches to understanding metabolic dysfunction and cardiovascular consequences of obstructive sleep apnea.

Authors:  Luciano F Drager; Vsevolod Y Polotsky; Christopher P O'Donnell; Sergio L Cravo; Geraldo Lorenzi-Filho; Benedito H Machado
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-07-31       Impact factor: 4.733

3.  Sleeping oxygen saturation, rapid eye movement sleep, and the adaptation of postprandial metabolic function in insulin sensitive and resistant individuals without diabetes.

Authors:  Karin A Garcia; William K Wohlgemuth; Ele Ferrannini; Andrea Mari; Alex Gonzalez; Armando J Mendez; Roberto Bizzotto; Jay S Skyler; Neil Schneiderman; Barry E Hurwitz
Journal:  Physiol Behav       Date:  2018-04-12

4.  Objectively measured sleep characteristics and prevalence of coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis Sleep study.

Authors:  Pamela L Lutsey; Robyn L McClelland; Daniel Duprez; Steven Shea; Eyal Shahar; Mako Nagayoshi; Matthew Budoff; Joel D Kaufman; Susan Redline
Journal:  Thorax       Date:  2015-07-08       Impact factor: 9.139

5.  Relationship between obstructive sleep apnea and nonalcoholic fatty liver disease in nonobese adults.

Authors:  Jia-Chao Qi; Jian-Chai Huang; Qi-Chang Lin; Jian-Ming Zhao; Xin Lin; Li-Da Chen; Jie-Feng Huang; Xiao Chen
Journal:  Sleep Breath       Date:  2015-07-15       Impact factor: 2.816

Review 6.  Adipose tissue inflammation by intermittent hypoxia: mechanistic link between obstructive sleep apnoea and metabolic dysfunction.

Authors:  Silke Ryan
Journal:  J Physiol       Date:  2017-01-25       Impact factor: 5.182

7.  Non-alcoholic fatty liver disease is an independent risk factor for inflammation in obstructive sleep apnea syndrome in obese Asian Indians.

Authors:  Surya Prakash Bhatt; Randeep Guleria; Naval K Vikram; A K Gupta
Journal:  Sleep Breath       Date:  2018-07-22       Impact factor: 2.816

8.  Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease.

Authors:  Shikha S Sundaram; Ronald J Sokol; Kelley E Capocelli; Zhaoxing Pan; Jillian S Sullivan; Kristen Robbins; Ann C Halbower
Journal:  J Pediatr       Date:  2013-12-07       Impact factor: 4.406

Review 9.  Insulin resistance, glucose intolerance and diabetes mellitus in obstructive sleep apnoea.

Authors:  Brian D Kent; Walter T McNicholas; Silke Ryan
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

10.  Intermittent hypoxia suppression of growth hormone and insulin-like growth factor-I in the neonatal rat liver.

Authors:  Charles Cai; Taimur Ahmad; Gloria B Valencia; Jacob V Aranda; Jiliu Xu; Kay D Beharry
Journal:  Growth Horm IGF Res       Date:  2018-03-08       Impact factor: 2.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.